What Orlistat STADA Treats: Main Uses and Benefits

Orlistat STADA is commonly used across domains where additional symptomatic support is needed for patients diagnosed with Obesity (defined by a Body Mass Index ge 30 kg/m^2). It is considered relevant for easing the symptom burden in those who are overweight (BMI ge 28 kg/m^2), and this therapeutic use is relevant in conditions marked by increased physiological stress. The medication is applied when appropriate alongside a supervised reduced-calorie, lower-fat diet and exercise program.

The therapeutic benefit may be part of symptomatic management applied across domains where additional symptomatic support is needed for symptoms related to systemic imbalance. This is relevant for managing symptoms related to systemic imbalance that often accompany these conditions, such as those associated with high blood pressure, elevated blood fats like cholesterol, and challenges with glucose tolerance. The medicine helps address symptom clusters that may become intense or disruptive, and is considered relevant for easing the challenge of long-term weight maintenance over time.

“The medication contributes to improved comfort during periods of heightened symptoms related to body weight.”

---

Quick Fact: Supportive Management for Symptom Clusters

Symptom Domain	Condition Category	Primary Benefit Focus
Elevated Body Mass Index	Chronic Obesity	Contributes to easing the overall symptom load
Systemic Imbalance	Metabolic Risk Factors	Assists with maintaining functional stability
Symptom Fluctuation	Weight Regain Prevention	Provides supportive relief when symptoms interfere with routine activities

Regulatory References

1. European Medicines Agency (EMA) Xenical Overview

Eligibility Map: Who Can and Cannot Use Orlistat STADA — Official Regulatory Information

---

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults and adolescents aged 12 years and older who meet established body mass index (BMI) criteria for obesity or being overweight with risk factors.

Populations for whom use is not recommended (if applicable):

• Individuals under 18 years for self-medication (OTC-strength); breastfeeding women.

Populations for whom use is contraindicated:

• Pregnant women; patients with chronic malabsorption syndrome; patients with cholestasis; patients with known hypersensitivity to the drug; patients taking cyclosporine.

Age-related eligibility rules:

• Children under 12 years: Safety and efficacy have not been established.

Condition-specific eligibility rules:

• Caution is required for patients with pre-existing liver disease, hypothyroidism, or those at risk for renal impairment (due to oxalate concerns).

Pregnancy and lactation eligibility status (if explicitly documented):

• Pregnancy is contraindicated. Lactation is contraindicated or use is not recommended.

Eligibility-related restrictions:

• Caution is advised for patients with a history of eating disorders.

---

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated (absolute prohibition); Established (approved use); Use Not Established (insufficient data); Caution/Monitoring Required (restricted use).

Regulatory basis (EMA / FDA / etc.): U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).

Eligibility-context constraints (as defined in official documents): Constrained by physiological state (e.g., pregnancy, malabsorption), comorbidity (e.g., cholestasis), age, and certain concomitant medications.

---

Resulting eligibility structure

Official eligibility statements:

• The medicine is contraindicated in patients with chronic malabsorption syndrome, cholestasis, and hypersensitivity.
• Use is contraindicated during pregnancy and breastfeeding.
• It is approved for use in adults and adolescents aged 12 years and older who meet specific BMI criteria.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define who can and cannot use Orlistat STADA by establishing explicit contraindications for populations with conditions that compromise nutrient absorption or liver health, or are in critical physiological states like pregnancy. Eligibility for use is formally restricted to specific age groups who meet the required BMI thresholds. Remaining populations are generally eligible for use, but require caution and monitoring if they have certain comorbidities.

Interactions with other medicines and products

Orlistat's primary mechanism of preventing fat absorption in the gut can interfere with the body's uptake of other essential substances and medicines. These interactions primarily involve a reduction in the absorption of concomitantly administered lipophilic (fat-soluble) drugs or vitamins, potentially leading to decreased efficacy or altered therapeutic effects.

Interacting Medicines and Products Requiring Special Attention

Category/Substance	Interaction Detail & Management Note
Fat-soluble Vitamins (A, D, E, K)	Absorption is reduced. A daily multivitamin supplement containing these vitamins should be taken at least two hours before or after Orlistat to ensure adequate levels.
Cyclosporine	Orlistat reduces the absorption of this immunosuppressant. Cyclosporine should be administered at least three hours apart from Orlistat, and blood levels must be closely monitored.
Warfarin/Oral Anticoagulants	Decreased Vitamin K absorption may alter the effectiveness of blood thinners, affecting INR values. Close and frequent monitoring of coagulation parameters is essential, and dosage adjustments may be required.
Levothyroxine	Absorption of this thyroid hormone may be reduced, potentially leading to hypothyroidism. These medicines should be taken at least four hours apart to minimize the risk of interaction.
Antiepileptic Medicines	Orlistat may decrease the plasma levels of some antiepileptics (e.g., lamotrigine, valproate), potentially leading to a loss of seizure control. Patients require careful monitoring.
Amiodarone	Reduced systemic exposure of this antiarrhythmic medicine may occur, lessening its therapeutic effect. Monitoring is recommended.
Antiretroviral Medicines for HIV	A risk of reduced absorption exists, which could compromise virologic control. HIV viral load must be closely monitored.

Co-administration of Orlistat with Acarbose should be avoided due to the lack of necessary interaction data.

Targeted Inhibition of Digestive Lipases

Orlistat functions as a reversible covalent inhibitor of gastric and pancreatic lipases, the primary enzymes involved in the breakdown of dietary fat. The mechanism is entirely peripheral, occurring exclusively within the gastrointestinal lumen. By chemically binding to a specific serine residue at the active site of these lipases, Orlistat blocks the dietary fat hydrolysis pathway . This prevents large triglyceride molecules from being converted into smaller, absorbable free fatty acids and monoglycerides.

Engineered Reduction of Net Systemic Caloric Intake

The resulting mechanistic cascade ensures that a significant portion of consumed fat remains undigested. Because triglycerides are too large for intestinal absorption, the undigested fat is excreted. This process creates an unabsorbed energy component, thereby directly reducing the net systemic caloric intake. The mechanism is strictly dependent on the presence of triglycerides in a meal, and its action consequently also reduces the absorption of fat-soluble vitamins.

Administration Guidelines

Orlistat STADA is administered orally as a 120 mg hard-gelatin capsule and follows a highly specific, meal-dependent regimen. The medication is to be used in conjunction with a reduced-calorie, nutritionally balanced diet where approximately 30% of total calories are derived from fat.

Dosing and Timing

The recommended dose is one 120 mg capsule taken three times a day, corresponding to the three main meals, with a maximum daily dose of 360 mg. The timing of administration is critical: each dose must be taken immediately before, during, or up to one hour after the main meal that contains fat. If a meal is missed or if the meal contains no fat, the dose of Orlistat STADA must be omitted entirely.

Procedural Use and Special Conditions

• Pediatric Use: For adolescents 12 years of age and older, the regimen is the same three-times-daily 120 mg dose.
• Vitamin Supplementation: Due to the medication's effect on fat absorption, a multivitamin supplement containing fat-soluble vitamins (A, D, E, and K) should be taken daily, with the instruction that it must be taken at least two hours before or after the Orlistat dose.
• Treatment Duration: The protocol specifies that treatment should be discontinued after 12 weeks if a minimum weight loss of 5% from the start of therapy has not been achieved.

These instructions establish a precise use protocol where correct administration is entirely dependent on the timing relative to meal consumption and adherence to the specified dietary composition.

Recent Clinical Evidence

Mechanism and Efficacy Overview

Orlistat is a medication that functions by inhibiting the pancreatic and gastric lipases, enzymes responsible for breaking down dietary fats (triglycerides) in the gut. By blocking these enzymes, orlistat prevents approximately 25% of consumed fat from being absorbed. This unabsorbed fat is then excreted from the body.

Clinical studies have explored the efficacy of orlistat in promoting weight loss in adults who are overweight or obese (Body Mass Index, or BMI, of 28 kg/m² or greater). Trials assessed orlistat use in conjunction with a reduced-calorie, low-fat diet.

Key Findings from Clinical Trials

Research has examined the differences in weight loss outcomes between patients taking orlistat and those taking a placebo, both while adhering to a defined diet plan. Findings consistently indicate that a greater percentage of patients treated with orlistat achieved clinically significant weight loss (defined as a 5% or 10% reduction from baseline body weight) compared to the placebo group. The primary observed effect is a reduction in fat absorption, which is associated with changes in body weight over a treatment period typically lasting six months or more.

Orlistat is also studied for its effect on related health markers. Trials have explored whether the weight loss achieved with orlistat is associated with changes in cardiovascular risk factors, such as blood pressure and cholesterol levels.

Safety and Tolerability

The most commonly reported side effects observed in clinical trials are gastrointestinal in nature. These events, which include oily spotting, flatulence with discharge, and frequent or urgent bowel movements, are generally related to the drug's mechanism of action (unabsorbed fat) and are often managed by adhering to a diet low in fat.

Key Studies & References

1. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial
2. Obesity: identification, assessment and management - NICE Guideline CG189 (Used for treatment criteria and weight loss targets)

Common questions about Orlistat STADA (FAQ)

---

Q: What is Orlistat STADA used for?

Orlistat STADA is a medication used to support weight loss in adults who are overweight or obese, typically in conjunction with a reduced-calorie, low-fat diet. It is generally recommended for individuals with a certain Body Mass Index (BMI) threshold, as outlined in the product information.

---

Q: How does Orlistat STADA work?

Orlistat STADA works in the digestive system to help prevent the absorption of some of the fat consumed in food. The unabsorbed fat is then passed out of the body in bowel movements. This mechanism may help reduce the overall calorie intake from dietary fat.

---

Q: What should I know about my diet while taking Orlistat STADA?

The official labeling information suggests that the medication should be taken with meals that contain some fat. To help manage potential gastrointestinal effects, it is generally recommended to follow a reduced-calorie diet where approximately 30% of calories come from fat. Following the recommended dietary structure, which is consistent with the product's intended use, is important.

---

Q: What are the possible side effects of Orlistat STADA?

Like many medications, Orlistat STADA may be associated with side effects, particularly those related to the digestive system. Common effects noted in clinical research may include oily spotting, gas with discharge, fatty or oily stools, and an increased need to have a bowel movement. These effects may be more pronounced if a person consumes meals high in fat. It is important to discuss all potential side effects and safety information with a healthcare provider.

---

Q: Does Orlistat STADA interact with other medications?

Yes, Orlistat STADA has the potential to interact with certain other medications and substances, including specific blood-thinners (like warfarin), some thyroid medications, certain HIV treatments, and fat-soluble vitamins (Vitamins A, D, E, and K). Due to the risk of reduced vitamin absorption, product labeling generally suggests considering a multivitamin supplement containing fat-soluble vitamins taken at a different time of day than the medication. Individuals should provide a full list of all current prescription and non-prescription products to a healthcare professional for review.

---

Q: What happens if I miss a dose of Orlistat STADA?

If a dose is missed, and it has been less than one hour since the meal, the product information generally suggests that the dose may still be taken. However, if more than an hour has passed since the meal, the missed dose should typically be skipped. The next scheduled dose should be taken with the next main meal as usual. It is important not to take a double dose to make up for a missed one, and any uncertainty should be discussed with a healthcare provider.

Official Storage and Disposal Requirements

Orlistat STADA must be stored according to strict regulatory specifications to maintain its quality and stability.

Packaging Type	Maximum Storage Temperature
Blister Packs	Do not store above 25 °C
Bottles	Do not store above 30 °C

The medicine requires protection from light and moisture; therefore, it must be stored in its original package and the container, if a bottle, must be kept tightly closed. All forms must be stored out of the reach and sight of children.

Disposal of unused or expired Orlistat must follow local pharmaceutical waste regulations. Medicines should not be disposed of via wastewater. Health authorities recommend using a drug take-back program or following specific household procedures for safe disposal of unused product.